期刊文献+

C-erbB_2、p53基因在卵巢癌组织中的表达及临床意义 被引量:1

Expression of C-erbB_2,p53 gene in ovarian cancer tissue
下载PDF
导出
摘要 目的:研究卵巢癌组织中C-erbB2、p53基因的表达情况及p53表达与增殖细胞核抗原(PCNA)的相关性。方法:选取我科2009年3月~2010年4月间临床确诊的卵巢癌患者病理组织80例,应用免疫组化SP三步法检测卵巢癌组织中C-erbB2、p53基因的表达情况及PCNA计数,并设同期20例正常卵巢组织为对照组,对比两组卵巢组织中C-erbB2、p53基因的表达及PCNA计数情况。结果:卵巢癌组织中C-erbB2、p53基因存在异常表达,p53蛋白表达阳性与阴性两组间PCNA计数差异有统计学意义(P<0.05),且卵巢癌临床分期与C-erbB2、p53基因阳性表达率呈正相关,临床分期Ⅲ、Ⅳ期C-erbB2、p53基因阳性表达率显著高于分期为Ⅰ、Ⅱ期的组织,组间比较差异有统计学意义(P<0.05)。结论:C-erbB2、p53基因的异常表达与卵巢癌的发生有关,其异常表达强度与肿瘤的分化及患者的预后相关。联合检测C-erbB2、p53基因的表达情况及PCNA计数,有助于准确判断卵巢癌的恶性程度及患者的预后。 Objective:To study the expression of C-erbBz and p53 genes in ovarian cancer and the correlation between the expression of p53 gene and proliferating cell nuclear antigen (PCNA). Methods: Pathologic tissues of 80 patients clinically diagnosed as ovarian cancer from March 2009 to April 2010 were chosen and immunohistochemica[ SP three-step method was used to detect the expression of C-erbB2 and p53 genes and PCNA count in ovarian cancer. Meanwhile, 20 cases of normal ovarian tissues were set as control group and the expression of C-erbB2 and p53 genes and PCNA count in two groups were observed for comparison. Results: C-erbB2 and p53 genes had abnormal expression in ovarian cancer tissues. There was significant difference in PCNA counts between positive expression of p53 gene and negative expression of p53 gene groups (P〈0, 05). There was positive correlation between clinical staging of ovarian cancer and the positive expression rate of p53 gene. The positive expression rates of C-erbB2 and p53 genes in
作者 李娟
出处 《海南医学院学报》 CAS 2013年第7期892-894,共3页 Journal of Hainan Medical University
基金 中国高校医学期刊临床专项资金项目(112210694)~~
关键词 卵巢癌 C-ERBB2 p53 增殖细胞核抗原(PCNA) 免疫组织化学 Ovarian cancer Cancer gene C-erbB2 Cancer suppressor gene p53 Proliferating cellnuclear antigen Immunohistochemistry
  • 相关文献

参考文献5

二级参考文献32

  • 1Beurel E, Jope R S. The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways[J].Prog Neurobiol,2006,79(4):173- 189.
  • 2Lin H, Changchien C C. Management of relapsed/refractory epithelial ovarian cancer: currents standards and novel approaches[J]. Taiwan J Obstet Gynecol,2007,46(4):379- 388.
  • 3McCubrey J A,Steelman L S, Abrams S L, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance [J].Adv Enzyme Regul, 2006,46:249-279.
  • 4Xing H, Weng D, Chen G, et al. Activation of fibronectin/PI3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells[J]. Cancer Lett,2008,261(1) : 108 -119.
  • 5Jope R S, Yuskaitis C J, Beurel E, et al. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics[J].Neurochem Res,2007,32(4-5) :577-595.
  • 6Jope R S,Johnson G V. The glamour and gloom of glycogen synthase kinase-3[J]. Trends Biochem Sci,2004,29(2):95 -102.
  • 7Watcharasit P, Bijur G N, Zmijewski J W, et al. Direct, activating interaction between glycogen synthase kinase 3beta and p53 after DNA damage[J]. Proc Natl Aead Sci U S A, 2002,99 (12) : 7951-7955.
  • 8Beurel E, Kornprobst M, Blivet Van Eggelpoel M J,et al. GSK-3beta reactivation with LY294002 seansitizes hepatoma cells to chemotherapy induced apoptosis[J]. Int J Oneol, 2005,27 (1) : 215-222.
  • 9Beurel E, Kornprobst M, Blivet Van Eggelpoel M J, et al. GSK3β inhibition by lithium confers resistance to chemotherapy-induced ap optosisthrough the repression of CD95 (Fas/APO-1) expression[J]. Exp Cell Res,2004,300(2) :354-364.
  • 10Rask K, Nilsson A, Brannstrom M,et al. Wnt signalling pathway in ovarian epithelial tumours: increased expression of beta -catenin and GSK3beta[J]. Br J Cancer,2003,89(7):1298-1304.

共引文献14

同被引文献1

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部